SCHEMBL4199229

SCHEMBL4199229

CCOC(=O)c1ccsc1NC(=O)c1ccc(F)cc1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.62
LMNA P02545 1/20 0.62
BRAF P15056 1/20 0.53
MAPT P10636 5/20 0.52
KMT2A Q03164 4/20 0.51
MEN1 O00255 3/20 0.51
CASP3 P42574 1/20 0.51
TRPV1 Q8NER1 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
CNR2 P34972 1/20 0.51
ALDH1A1 P00352 1/20 0.51
HPGD P15428 1/20 0.51
THRB P10828 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MAPK10 P53779 2/20 0.48
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HTT P42858 1/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16264406 0.83 CYP2C9 (0.53) KDM4ELMNABRAFCNR2HPGD
SCHEMBL4193588 0.79 MAPK8 (0.57) KDM4ELMNAMAPTKMT2AMEN1
SCHEMBL11638233 0.79 PTK2 (0.59) KDM4ELMNAMAPTKMT2AMEN1
SCHEMBL15440489 0.78 HPGD (0.53) KDM4EMAPTKMT2AMEN1ALDH1A1
SCHEMBL16264474 0.77 CYP2C9 (0.55) KDM4ELMNASMN1; SMN2MAPK10
SCHEMBL9396580 0.77 MEN1 (0.48) KDM4ELMNAMAPTKMT2AMEN1
SCHEMBL9398335 0.76 PKM (0.47) KDM4ELMNAMAPTKMT2AMEN1
SCHEMBL28802106 0.76 ALOX12 (0.64) KDM4ELMNAMAPTKMT2AMEN1
SCHEMBL4634907 0.75 MAPT (0.81) KDM4ELMNABRAFMAPTKMT2A
SCHEMBL6636910 0.75 TSHR (0.46) KDM4ELMNAMAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 GPBAR1, GPR119, GRK5 KDM4E 3848/4885LMNA 4082/4885BRAF 3587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.